The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | Outcomes of older patients with primary CNS lymphoma
Nicolas Martinez-Calle, MD, MSc, Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses outcomes of older patients with primary CNS lymphoma treated in routine clinical practice in the UK. The data was published in The British Journal of Haematology and found that methotrexate dose intensity correlated with response and survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
